

4th August, 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 10th February, 2026 regarding the Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. ("InvaGen"), a wholly-owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, we hereby inform you that InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani